BACKGROUND: In 2004, the Survey on Drug Use and Health showed that 5% of American women reported use of an illicit drug during pregnancy. The results of studies determining the association between periconceptional illicit drug use and birth defects have been inconsistent. METHODS: We analyzed data from the National Birth Defects Prevention Study, a case-control study of major birth defects, and assessed all birth defects categories in which there were at least 250 interviewed case mothers. We included 10,241 infants with major congenital malformations (case infants) and 4,967 infants without major congenital malformations (control infants) born between 1997 and 2003 for whom there was a completed maternal interview with detailed information on prenatal illicit drug use and potential confounders. We used multivariable logistic regression to estimate the associations between cannabis, cocaine, and stimulant use in the month before pregnancy or during the first trimester (periconceptional period) and the occurrence of selected birth defects. RESULTS: In the periconceptional period, 5% of the 15,208 mothers reported any use of illicit drugs. We did not find associations between illicit drug use and most of the 20 eligible categories of congenital malformations. Periconceptional cannabis use seemed to be associated with an increased risk of anencephaly (adjusted odds ratio = 1.7; 95% confidence interval = 0.9-3.4), whereas cocaine use in the periconceptional period was associated with the risk of cleft palate (2.5; 1.1-5.4). CONCLUSIONS: There were very few suggestions of positive associations between periconceptional illicit drug use and the 20 birth defects categories.
BACKGROUND: In 2004, the Survey on Drug Use and Health showed that 5% of American women reported use of an illicit drug during pregnancy. The results of studies determining the association between periconceptional illicit drug use and birth defects have been inconsistent. METHODS: We analyzed data from the National Birth Defects Prevention Study, a case-control study of major birth defects, and assessed all birth defects categories in which there were at least 250 interviewed case mothers. We included 10,241 infants with major congenital malformations (case infants) and 4,967 infants without major congenital malformations (control infants) born between 1997 and 2003 for whom there was a completed maternal interview with detailed information on prenatal illicit drug use and potential confounders. We used multivariable logistic regression to estimate the associations between cannabis, cocaine, and stimulant use in the month before pregnancy or during the first trimester (periconceptional period) and the occurrence of selected birth defects. RESULTS: In the periconceptional period, 5% of the 15,208 mothers reported any use of illicit drugs. We did not find associations between illicit drug use and most of the 20 eligible categories of congenital malformations. Periconceptional cannabis use seemed to be associated with an increased risk of anencephaly (adjusted odds ratio = 1.7; 95% confidence interval = 0.9-3.4), whereas cocaine use in the periconceptional period was associated with the risk of cleft palate (2.5; 1.1-5.4). CONCLUSIONS: There were very few suggestions of positive associations between periconceptional illicit drug use and the 20 birth defects categories.
Authors: Marleen M H J van Gelder; A Rogier T Donders; Owen Devine; Nel Roeleveld; Jennita Reefhuis Journal: Paediatr Perinat Epidemiol Date: 2014-08-26 Impact factor: 3.980
Authors: Delphine Psychoyos; K Yaragudri Vinod; Jin Cao; Shan Xie; Richard L Hyson; Bogdan Wlodarczyk; Weimin He; Thomas B Cooper; Basalingappa L Hungund; Richard H Finnell Journal: Birth Defects Res B Dev Reprod Toxicol Date: 2012-02-06
Authors: Hyeyeun Lim; A J Agopian; Lawrence W Whitehead; Charles W Beasley; Peter H Langlois; Robert J Emery; Dorothy Kim Waller Journal: Birth Defects Res A Clin Mol Teratol Date: 2015-03-28
Authors: Jennifer N Lind; Julia D Interrante; Elizabeth C Ailes; Suzanne M Gilboa; Sara Khan; Meghan T Frey; April L Dawson; Margaret A Honein; Nicole F Dowling; Hilda Razzaghi; Andreea A Creanga; Cheryl S Broussard Journal: Pediatrics Date: 2017-06 Impact factor: 7.124